Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse EventsHideki Iwamoto, Takuji Torimura, Atsutaka Masuda et al.|Cancers|2020Cited by 68
Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical PracticeHideki Iwamoto, Shigeo Shimose, Yu Noda et al.|Cancers|2021Cited by 59
Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular CarcinomaHideki Iwamoto, Takashi Niizeki, Hiroaki Nagamatsu et al.|Cancers|2021Cited by 32
Clinical Importance of Regimens in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macrovascular InvasionTakashi Niizeki, Takuji Torimura, Hideki Iwamoto et al.|Cancers|2021Cited by 25
Tumor‐derived insulin‐like growth factor‐binding protein‐1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitorsHiroyuki Suzuki, Takuji Torimura, Hideki Iwamoto et al.|癌症：英文版|2023Cited by 23